NCT02146313View on ClinicalTrials.gov

A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 22, 2014

Primary Completion Date

June 18, 2018

Study Completion Date

June 18, 2018

Conditions
Pancreatic NeoplasmsOvarian Neoplasms
Interventions
DRUG

DMUC4064A

Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).

Trial Locations (7)

34232

Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota

37203

Sarah Cannon Research Inst., Nashville

53792

University of Wisconsin, Madison

73104

Oklahoma University Health Sciences Center, Oklahoma City

02114

Massachusetts General Hospital., Boston

02115

Dana Farber Cancer Inst., Boston

07601

Hackensack Univ Med Ctr, Hackensack

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT02146313 - A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter